Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE) | Transthyretin amyloidosis (ATTR) | Phase 3 | Clinical Pause | Intravenous | Genetic Disorder |
| Regeneron Pharmaceuticals Inc. | REGN5713-5714-5715 | Allergic rhinoconjunctivitis, allergic rhinitis | Phase 3 | Ongoing | Intravenous | Antihistamine |
| Regeneron Pharmaceuticals Inc. | Odronextamab - (OLYMPIA) | Non-Hodgkin Lymphoma (NHL) | Phase 3 | Data Released | Intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | EYLEA (aflibercept) - (PULSAR) | Wet age-related macular degeneration (AMD) | Phase 3 | Data Released | Intravitreal | Opthalmic |
| Regeneron Pharmaceuticals Inc. | DUPIXENT (dupilumab) - (CUPID STUDY C) | Chronic Spontaneous Urticaria (CSU) | Phase 3 | Data Released | Subcutaneous | Immunology |
| Regeneron Pharmaceuticals Inc. | KEVZARA (sarilumab) | Coronavirus COVID-19 | Phase 3 | Trial Discontinued | Subcutaneous | COVID-19 |
| Regeneron Pharmaceuticals Inc. | KEVZARA (sarilumab) | Coronavirus COVID-19 | Phase 3 | Trial Discontinued | Subcutaneous | COVID-19 |
| Regeneron Pharmaceuticals Inc. | Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE) | Transthyretin amyloidosis (ATTR) | Phase 3 | Clinical Pause | Intravenous | Genetic Disorder |
